Hite Christopher
SEC CIK 1814238 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RPRX | Royalty Pharma plc | EVP, Vice COB | 270.4K | — | $27.36M | 14 | 2024-05-13 | 2026-09-22 |
Most active insiders at RPRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Coyne Terrance P. | EVP, CFO | — | $38.96M |
| 2 | Hite Christopher | EVP, Vice COB | — | $27.36M |
| 3 | Lloyd George W. | EVP, CLO, Investments | — | $13.81M |
| 4 | Urist Marshall | EVP, Research, Investments | — | $12.07M |
| 5 | Norden Gregory | Dir | — | $161.4K |
| 6 | Engelbert Catherine M. | Dir | — | — |
| 7 | Ho Carole | Dir | — | — |
| 8 | Coric Vlad | Dir | — | — |
| 9 | Bassler Bonnie L | Dir | — | — |
| 10 | Legorreta Pablo G. | CEO, COB, Dir | — | — |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MTI | 2026-09-24 16:10 | 2026-09-22 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $58.53 | -100.0K | 270.4K | -27% | -$5.85M |
| TI | 2026-08-19 16:20 | 2026-08-18 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $59.97 | -100.0K | 370.4K | -21% | -$6.00M |
| T | 2026-08-19 16:20 | 2026-08-19 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, COB, Partnering | G - Gift | $0.00 | -16.8K | 23.2K | -42% | $0 |
| I | 2026-08-07 17:12 | 2026-08-05 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, COB, Partnering | A - Grant | $0.00 | +11.0K | 470.4K | +2% | $0 |
| MTI | 2026-07-02 16:08 | 2026-06-30 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $56.52 | -100.0K | 459.4K | -18% | -$5.65M |
| MT | 2026-07-02 16:08 | 2026-06-30 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $56.46 | -30.0K | 40.0K | -43% | -$1.69M |
| MTI | 2026-06-25 17:11 | 2026-06-23 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $54.40 | -150.0K | 559.4K | -21% | -$8.16M |
| I | 2026-05-08 17:12 | 2026-05-06 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, Vice COB | A - Grant | $0.00 | +24.3K | 709.4K | +4% | $0 |
| I | 2026-02-13 | 2026-02-11 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, Vice COB | A - Grant | $0.00 | +26.6K | 685.1K | +4% | $0 |
| I | 2025-11-07 | 2025-11-05 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, Vice COB | A - Grant | $0.00 | +6,168 | 658.5K | +0.9% | $0 |
| I | 2025-08-08 | 2025-08-06 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, Vice COB | A - Grant | $0.00 | +3,696 | 652.3K | +0.6% | $0 |
| I | 2025-05-09 | 2025-05-08 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, Vice COB | A - Grant | $0.00 | +48.6K | 648.6K | +8% | $0 |
| DI | 2025-02-18 | 2025-02-14 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, Vice COB | C - Cnv Deriv | $0.00 | +300.0K | 600.0K | +100% | $0 |
| DI | 2024-05-16 | 2024-05-13 | RPRX | Royalty Pharma plc | Hite Christopher | EVP, Vice COB | C - Cnv Deriv | $0.00 | +300.0K | 370.0K | +429% | $0 |
Purchase Sale Sale after option exercise All abbreviations